KCT0000689尚未招募未知
A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and Thioctic acid after oral administration in healthy male volunteers
nimed Pharm0 个研究点目标入组 42 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1) Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2
- •2) Provision of signed written informed consent
- •3) Acceptable physical examination and clinical examination, during screening
排除标准
- •1) A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
- •2) A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
- •3) A subject with history of allergies including study drug (pregabalin or thioctic acid) or other drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
- •4) A subject whose lab test results are as follows: AST(SGOT), ALT(SGPT) > 1.5 x upper limit of reference range
- •5) Presence or history of drug abuse or positive result in urine drug screening test
- •6) Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)
- •7) Participation in clinical trials of any drug within 60 days prior to the participation of the study
- •8) Blood donation during 2 months or apheresis during 1 month before the study
- •9) Use of alcohol over 21 units/weeks
- •10) Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during the study period (from 24 hours before hospitalization to discharge)
- •11) Use of caffeine drink during the study period(from 24 hours before hospitalization to discharge)
- •12) A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products during the study
- •13) Judged to be inappropriate for the study by the investigator after reviewing clinical laboratory results or other reasons.
研究者
相似试验
已完成
不适用
Clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and Tramadol ER after oral administration in healthy male volunteersKCT0002657Sam Chun Dang Pharm.24
已完成
不适用
Evaluating a Pharmacokinetic Drug Interaction between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male SubjectsEndocrine, nutritional and metabolic diseaseKCT0000889Hanmi Pharm36
已完成
1 期
An Open-label, Randomised, Crossover Study to Assess Fasted Versus Fed Bioavailability of Radiprodil in Healthy Adultsglutamate receptor ionotropic N-methyl-D-aspartate (GRIN) related disorder - neurodevelopmental syndromesNeurological - Other neurological disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12624000102572GRIN Therapeutics, Inc.18
进行中（未招募）
1 期
An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.ot applicable (submitted trial is a bioequivalence study in healthy subjects)MedDRA version: 20.0Level: HLGTClassification code: 10047438Term: Viral infectious disorders Class: 10021881CTIS2023-504760-42-00Dermax30
已完成
不适用
An open-label, exploratory, randomised, three-period, six-sequence single dose crossover study comparing the safety, tolerability and pharmacokinetic profile of a new and marketed flurbiprofen (8.75 mg) spray in healthy male/female subjects under fasting conditions.Ear, nose and throat diseasesSore throatNL-OMON48429Reckitt Benckiser Healthcare (UK) Limited16